Stem cell therapy for diabetes (type 1 & type 2)

Diabetes Mellitus

Millions of people on our planet are diagnosed with 'Diabetes Mellitus'. The sad thing is that the number of people with diabetes is growing. Scientists have rightly entitled this disease as one of the most common and threatening diseases, along with cancer and AIDS.

According to statistics, only 10% of patients have insulin-dependent diabetes, 90% are people with type II disease who have gotten it in virtue of an unhealthy lifestyle.

Diabetes Mellitus is a persistent and perpetual metabolism disorder.

It is characterized by the lack of pancreatic insulin-producing cells (islet β-cells) due to autoimmune reactions. Scientific studies have shown that beta-cells targeting autoantibodies that appear many months or even years before the disease symptoms. Production of such antibodies is possible only if autoantigens from β-cells have been processed and specifically recognized by dysregulated immune system cells, such as antigen-presenting dendritic cells, T-cells, B-cells. Autoimmune reactions lead to the gradual destruction of β-cells resulting in depletion of the insulin-production capacity of the pancreas.

What is the potential for embryonic stem cells to treat diabetes?

It is obvious that each certain type of stem cell such as mesenchymal, embryonic stem cells or umbilical cord blood stem cells that are used in the majority of stem cell clinics as monotherapy, cannot be equally efficient for the treatment of a variety of different tissues that can be affected in diabetes mellitus.

For instance, umbilical cord blood (allogeneic or autologous mesenchymal stem cells) have only hematopoietic stem cells which not enough for complex treatment of diabetes mellitus. Meanwhile, fetal stem cell therapy consists of a combination of different organ-specific types of stem cells that can treat all the diseased organs and systems.

Clinical trials in regenerative medicine demonstrated that transplantation of embryonic stem cells could lead to tumor formation in the recipient.

Fetal stem cells in type 1 and 2 Diabetes Mellitus

Promising treatment approach aiming to improve the health condition of patients suffering from diabetes mellitus is the administration of the stem cells. These cells have a remarkable feature to migrate into the place of injury and facilitate regeneration of damaged tissue due to the substitution of damaged and dying cells with the new one and due to the release of trophic factors supporting the functional activity of the tissues and enhancing blood supply of the injured area.

Another important benefit of stem cell treatment is stem cells' pronounced immunomodulatory properties. Owing to complex interactions of stem cells with the immune system, stem cell treatment can decrease the activity of antigen-presenting dendritic cells, T-cells, beta-cells that are involved in the pathogenesis of diabetes mellitus type 1. Multiple types of research have provided evidence that human fetal stem cells can develop into cells that can and do produce insulin. These cells proliferate (continue to replicate) and differentiate (specialize) into functioning islet tissue.

Thus, it is reasonable to use a combination of different organ-specific types of stem cells corresponding to the affected organs of the patient.

In order to achieve better treatment results, specialists of Infinity Clinic have developed a personalized stem cell therapy approach that is based on the administration of several different types of organ-specific stem cells according to individual health status and specific complications of each particular patient.

Our results in Diabetes

Infinity Clinic offers advanced and highly effective fetal progenitor stem cell therapy for treating type 1 diabetes mellitus and type 2, preventing diabetes-related complications.

In combination with routine therapy, in type 1 diabetes mellitus, fetal progenitor cells are intended to:

• partially restore the pancreas (with fetal pancreatic progenitor stem cells)
• terminate auto-aggression against beta-cells
• prevent further destruction of remaining β-cells, restore them and their functional capacity (helping insulin-producing cells to do their job)
• prevent diabetes-associated complications (cardiovascular disease, neurologic, eye disease, kidney issues etc.)
• improve insulin-dependent tissue and insulin secretion condition
• restore endothelial cells of blood vessels damaged by glycosylated hemoglobin

In type 2 diabetes, fetal progenitor stem cells are intended to:

• restore tissue sensitivity to insulin
• improve glucose metabolism
• decrease glucose and pathologic lipids production by islet and liver cells
• strengthen artery walls for the prevention of atherosclerosis and related complications

Diabetes type 1, Patent UA 126024 || Patent UA 118431

Diabetes type 2, Patent UA 126019 || Patent UA 118430

After stem cells have been administered into the patient`s body they have to make their way to the correct place (e.g. area of damage) and then have their desired effect. Stem cells attach themselves to the tissues of the damaged pancreas and then transform into more active cells.

This process takes time, from several weeks to several months, to see the full desired effect.

Over the years, our patients report the following improvements:

• better glycemic control (significant and lasting decrease of both fasting and post-prandial blood sugar)
• up to 50% gradual decrease in insulin requirement/reduction of oral hypoglycemic medicines dose
• significant and lasting increase of C-peptide, which means insulin production improvement
• significant and lasting decrease of glycosylated hemoglobin (HbA1C) proving better diabetes management
• formation of the new arteries and strengthening of the existing ones, which ensures better circulation
• higher hemoglobin and red blood count
• relief of chronic diabetes-associated such as diabetic retinopathy, diabetic nephropathy, diabetic macrovascular pathological changes, diabetic peripheral neuropathy, and diabetic autonomic neuropathy
• healing of trophic ulcers and foot tissue defects
• the higher energy level and exercise power
• sexual capacity increase
• powerful immune-boosting
• improved life quality

Effects in diabetes-associated complication

In diabetic retinopathy, stem cell therapy helps to restore the damaged eye retina, while new blood vessels developing as a result of it improve blood supply to the eyes, which helps to improve and save eyesight.

Powerful immune boosting makes the body less susceptible to all kinds of infections, which helps to stop soft tissue deterioration in the case of diabetic angiopathy.

Fetal progenitor stem cells are also effective in diabetes-associated encephalopathy, kidney disease, and other complications.

Infinity Clinic offers unique organ-specific fetal progenitor stem cell therapy targeting the cause of the disease, not just the symptoms.

The main advantage of our method is the absence of any risks or side effects.

Our recommendation

Current studies and our experience indicate cumulative effect from multiple stem cell therapies, therefore treatment should be repeated. In general, top-up timing depends on the severity of the case. We offer long-term follow-up and will recommend the best time to repeat the course.

Optimal results presuppose a combination of fetal progenitor stem cell therapy with routine treatment, giving up bad habits, keeping the diet, and regular exercising.

How to apply for Diabetes treatment

We wish to offer you the best possible treatment, therefore we need to study the case thoroughly and kindly ask you to fill the short form that we will send you an e-mail medical records available to info@infinityclinic.com

We are looking forward to welcoming you for treatment and help you in the best possible way.

Welcome to Infinity!